Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography

Recent Results in Cancer Research

Volumn 196, Issue , 2012, Pages 201-211

  Lordick, Florian ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN;

ANTIGEN EXPRESSION; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS SURGERY; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT SELECTION; PHARMACOLOGICAL PARAMETERS; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; QUALITY CONTROL; REFERENCE VALUE; REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; STANDARDIZED UPTAKE VALUE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED STATES;

EID: 84869998292     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-31629-6_14     Document Type: Review

References (37)

1. Boellaard R, Krak NC, Hoekstra OS et al (2004) Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 45: 1519-1527
2. Boellaard R, Oyen WJ, Hoekstra CJ et al (2008) The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 35: 2320-2333
3. Brücher BL, Weber W, Bauer M et al (2001) Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233: 300-309
4. Downey RJ, Akhurst T, Ilson D et al (2003) Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21: 428-432
5. Flamen P, Lerut A, Van Cutsem E et al (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18: 3202-3210
6. Flamen P, Van Cutsem E, Lerut A et al (2002) Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13: 361-368
7. Fletcher JW, Djulbegovic B, Soares HP et al (2008) Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 49: 480-508
8. Gillham CM, Lucey JA, Keogan M et al (2006) (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 95: 1174-1179
9. Herrmann K, Ott K, Buck AK et al (2007) Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J Nucl Med 48: 1945-1950
10. Ilson DH, Minsky BD, Ku GY et al (2011) Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer. doi: 10.1002/cncr.26591. (Epub ahead of print)
11. Javeri H, Xiao L, Rohren E et al (2009) The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer 115: 5184-5192
12. Kim MK, Ryu JS, Kim SB et al (2007) Value of complete metabolic response by (18)Ffluorodeoxyglucose- positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 43: 1385-1391
13. Klaeser B, Nitzsche E, Schuller JC et al (2009) Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). Onkologie 32: 724-730
14. Levine EA, Farmer MR, Clark P et al (2006) Predictive value of 18-fluoro-deoxy-glucosepositron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 243: 472-478
15. Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8: 797-805
16. Lordick F, Ruers T, Aust DE et al (2008) European organisation of research and treatment of cancer (EORTC) gastrointestinal group: workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer 44: 1807-1819
17. Monjazeb AM, Riedlinger G, Aklilu M et al (2010) Outcomes of patients with esophageal cancer staged with [18F] fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection. J Clin Oncol 28 (31): 4714-4721
18. Ott K, Weber WA, Lordick F et al (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24: 4692-4698
19. Peng HQ, Halsey K, Sun CC et al (2009) Clinical utility of postchemoradiation endoscopic brush cytology and biopsy in predicting residual esophageal adenocarcinoma. Cancer Cytopathol 117: 463-472
20. Räsänen JV, Sihvo EI, Knuuti MJ et al (2003) Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 10: 954-960
21. Ribi K, Koeberle D, Schuller JC et al (2009) Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation? Support Care Cancer 17: 1109-1116
22. Rizk N, Downey RJ, Akhurst T et al (2006) Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg 81: 1076-1081
23. Rizk NP, Tang L, Adusumilli PS et al (2009) Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol 4: 875-879
24. Sarkaria IS, Rizk NP, Bains MS et al (2009) Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg 249: 764-767
25. Schomburg A, Bender H, Reichel C et al (1996) Standardized uptake values of fluorine-18 fluorodeoxyglucose: the value of different normalization procedures. Eur J Nucl Med 23: 571-574
26. Shields AF (2012) PET imaging of tumor growth: not as easy as it looks. Clin Cancer Res 18: 1189-1191
27. Shields AF, Grierson JR, Dohmen BM et al (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4: 1334-1336
28. Swisher SG, Erasmus J, Maish M et al (2004) 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101: 1776-1785
29. Vallböhmer D, Hölscher AH, Dietlein M et al (2009) [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 250: 888-894
30. van Heijl M, Omloo JM, van Berge Henegouwen MI (2011) Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 253 (1): 56-63
31. van Vliet EP, Heijenbrok-Kal MH, Hunink MG et al (2008) Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 98: 547-557
32. van Westreenen HL, Cobben DC, Jager PL et al (2005) Comparison of 18F-FLT PET and 18FFDG PET in esophageal cancer. J Nucl Med 46: 400-404
33. van Westreenen HL, Westerterp M, Bossuyt PM et al (2004) Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22: 3805-3812
34. Vrieze O, Haustermans K, De Wever W et al (2004) Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? Radiother Oncol 73: 269-275
35. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50 (Suppl 1):122S-150S
36. Weber WA, Ott K, Becker K et al (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19: 3058-3065
37. Wieder HA, Beer AJ, Lordick F et al (2005) Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 46: 2029-2034